Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== C-terminal modifications === The C-terminus of proteins can be modified posttranslationally, most commonly by the addition of a lipid anchor to the C-terminus that allows the protein to be inserted into a membrane without having a transmembrane domain.
Le Havre belongs to the Paris Basin which was formed in the Mesozoic period. The Paris Basin consists of sedimentary rocks. The commune of Le Havre consists of two areas separated by a natural cliff edge: one part in the lower part of the town to the south including the harbour, the city centre and the suburbs. It was built on former marshland and mudflats that were drained in the 16th century. The soil consists of several metres of alluvium or silt deposited by the Seine. The city centre was rebuilt after the Second World War using a metre of flattened rubble as a foundation. The upper town to the north, is part of the cauchois plateau: the neighbourhood of Dollemard is its highest point (between 90 and 115 metres (295 and 377 feet) above sea level). The plateau is covered with a layer of flinty clay and a fertile silt. The bedrock consists of a large thickness of chalk measuring up to 200 m (656 ft) deep. Because of the slope the coast is affected by the risk of landslides.
Proteins can be engineered to improve the chance of successful protein crystallization. A common way is by trimming the recombinant construct to remove N- and C- terminal parts, which are frequently disordered or poorly structured ("high entropy"). Surface entropy reduction entails replacing surface residue clusters with high conformational entropy (usually lysine, glutamate, and glutamine) with alanines. In a similar vein, replacing lysine with arginine in bulk has proven useful. It is also possible to engineer in crystal contacts by mutating residues. An even more advanced method involves the use of "chaperone" proteins known to be more crystallizable. This can be achieved by designing a fusion protein consisting of the protein with unknown structure and a protein domain known to crystalize well. The interaction in question can also be intermolecular, for example between the candidate protein and some antibody Fab fragments selected to bind tightly to the protein, or between a candidate-maltose-binding protein (MBP) fusion and a protein specifically designed to bind MBP. Many methods for protein engineering require some forward knowledge of protein structure, either simply knowing what residues are surface or buried or knowing the full tertiary structure. Modern protein structure prediction tools are largely sufficient. It is also possible to predict the result of crystallization using these methods. Cystine residues on the surface tend to cause trouble for recombinant protein production by causing aggregation. They can be replaced with alanines.
This gives the antivenin its polyvalent property. This also enhances the potency of the antivenin. Some venoms cannot induce the immune system enough on its own or the combination of two or more venoms result in a better responding antivenin.
=== 16 April === The SBU claimed to have destroyed a Russian Nebo-U radar system in Bryansk Oblast using drones. Russian-installed officials in Zaporizhzhia Oblast said that Anton Yakimenko, a member of the district council of occupied Yakymivka, was lightly injured in a bomb attack as part of an assassination attempt. Ukraine announced that it was testing an "unmanned submarine" that can be fitted with a warhead, stealth features and sensors, carry up to 10 divers, carry six torpedoes or missiles and has an endurance of 54 hours/1000 km, with a speed of up to 50 km/h underwater. Zelenskyy signed the revised mobilization bill into law. Denmark announced a new military aid package for Ukraine valued at 2.2 billion kroner ($313 million) that is partly aimed at weapons production in the Czech Republic.
Sources: en.wikipedia.org
=== Shark repellent === P. marmoratas and P. pavoninus release pardaxin when threatened by sharks. Pardaxin targets the gills and pharyngeal cavity of the sharks. It results in severe struggling, mouth paralysis, and temporary increase of urea leakage in the gills. This distress is caused by the attack of the cellular membrane of the gills, which causes a large influx of salt ions. Research into creating a commercial shark repellent using pardaxin was discontinued because it dilutes in the water too quickly. It is only effective if sprayed almost directly into a shark's mouth.
Risk factors for opioid overdose include opioid dependence, injecting opioids, using high doses of opioids, and use together with alcohol, benzodiazepines, or cocaine. The risk is particularly high following detoxification. Dependence on prescription opioids can occur from their use to treat chronic pain. In young children, an overdose is usually due to opioids that are intended for their parents, older siblings, or grandparents. In mothers who take codeine during breastfeeding, opioid overdoses have occurred in their baby. Codeine is, therefore, not recommended for those who are breastfeeding.
==== CYP450 ==== Cytochrome P450 is a very large family of haemoproteins (hemoproteins) that are characterized by their enzymatic activity and their role in the metabolism of a large number of drugs. Of the various families that are present in humans, the most interesting in this respect are the 1, 2 and 3, and the most important enzymes are CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. The majority of the enzymes are also involved in the metabolism of endogenous substances, such as steroids or sex hormones, which is also important should there be interference with these substances. The function of the enzymes can either be stimulated (enzyme induction) or inhibited (enzyme inhibition).
February 9 The second impeachment trial of Donald Trump begins. He is acquitted four days later, February 13 with a 57–43 vote in the Senate, ten votes short of the required two-thirds majority for conviction. COVID-19 drug development: The FDA issues an emergency use authorization (EUA) for bamlanivimab and etesevimab. February 11 President Biden terminates the national emergency declaration on the US-Mexico border which President Trump had used to pay for the wall. In Fort Worth, Texas, at least six people are killed in an accident involving 133 vehicles on Interstate 35W, affected by weather conditions left by a snowstorm system. February 12 The United States Senate votes by unanimous consent to award United States Capitol Police officer Eugene Goodman the Congressional Gold Medal for keeping rioters away from the Senate chamber during the storming of the United States Capitol. The U.S. Food and Drug Administration approves Cosela as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression. February 15 – House Speaker Nancy Pelosi announces that Congress will establish a 9/11-styled commission to investigate the January 6 riot at the United States Capitol. February 13–17 – A major winter storm kills 58 people in the United States (and 12 in Mexico) and causes over 9,724,000 power outages across 13 states in the Midwest and Southwest, with Southwest Power Pool declaring an "energy emergency". February 17 COVID-19 pandemic: North Dakota confirms their first case of the UK variant of SARS-CoV-2.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.